Dr. Kan graduated from National Tsinghua University in Taiwan and completed post-doctoral research at Tsukuba University in Japan. He served as Associate Director of the Taiwan Liposomal Company, a Researcher at the Biomedical Engineering Center of the Industrial Technology Research Institute, and a Researcher at Tsukuba University in Japan. He has worked in the pharmaceutical industry for more than 20 years, focused on pharmaceutical formulation technology and product development, published over 50 papers and more than 10 patents related to drug delivery, some of which have been used in clinical products. In addition, he has led the development of several new formulation-based drug projects and completed filing and listing of IND, BioIND, and ANDA products in Taiwan, China, the United States, Japan, and Europe. He is now the President of Pharmosa.
Hui-An PaoVice President of Operations
Mr. Pao has over 30 years of experience in pharmaceutical manufacturing operations and supply chain management. Prior to joining Pharmosa, he served for Taiwan Liposome Company (TLC) and held positions as manufacturing development senior director, where he was responsible for outsourcing management, CMC operations, manufacturing transfer and purchasing activities. Before the Taiwan Liposome Company, Mr. Pao served for Taiwan Yamanouchi Pharmaceutical (now Astellas Pharma). During his time with Yamanouchi, Mr. Pao held various positions including technical services, QA/QC manager, responsible for validation activities and GMP plant management. After that he served as a manager of regulatory affairs in charge of drug registration. Mr. Pao holds a bachelor degree from the Department of Pharmacy, Chia Nan University of Pharmacy & Science. He also has a pharmacist certificate.
Peter LinDirector, Research and Development
Mr. Lin graduated from the department of chemical engineering at NCHU and has worked for more than 16 years in the pharmaceutical industry. He specializes in the development of DDS products, new drug formulations (505b2), and combining them with medical devices. He has obtained 8 DDS patents, and published 3 journal articles and 20 seminar papers. Mr. Lin joined ITRI after graduating with a master's degree. His experience includes an oral peptide drug delivery system and a patent application for it, as well as screening two kinds of BBB Targeting Ligands and applying for patent protection for them. He joined TLC in 2006, developed one specialty product, and applied for patent protection of the formulation. Two new liposome formulation projects are under pre-clinical research.
Winny YangDirector, Finance and Administration
Ms. Yang graduated from the Department of Accountancy and the Graduate Institute of Finance from National Cheng Kung University. She brings Pharmosa 15 years of experience in financial and accounting, capital market fundraising and M&A. Prior to joining Pharmosa, Ms. Yang was Senior Vice President of the Investment Banking Department at KGI Securities Co. Ltd. and led 12 IPO projects, 14 SPO projects, 7 M&A projects, and pre-IPO consultation. She also participated in TaiGen Biotech’s (TPEx: 4157) US$1.1 billion initial public offering on the Taipei Exchange. Ms. Yang has expertise in investment structure planning, joint ventures, corporate reorganization, corporate governance, auditing and internal control, personnel optimization, business development, and strategic planning. Ms. Yang started her career with KPMG as a financial auditor.
Dr. Han received her bachelor degree in Veterinary Medicine from Taiwan University and master degree and doctorate from The University of Tokyo (Japan). She was a Director of the Taiwan Liposomal Company, Study Director in preclinical toxicology division of Green Season Biotech Co. (Taiwan), Visiting Scholar at The University of Tokyo (Japan), Study Director/Research Fellow at Research Institute for Animal Science in Biochemistry & Toxicology (RIAS) (Japan), and Veterinary Researcher in Central Experimental Institute of Liberia (West Africa), and Veterinary Officer in Ministry of Agriculture of Liberia (West Africa). She has more than 3 decades of experiences in preclinical experiments, running general toxicity studies, reproduction/ developmental toxicity study, pharmacokinetic/toxicokinetic studies, setting up/efficacy valuation for animal disease models etc., as well as preparation of IND/ANDA documents for submission. Additionally, she was a team member for animal toxicology studies in “High Production Volume Chemicals Assessment Programme "which was advocated by OECD at 90". She is now a consultant of Pharmosa in terms of preclinical experiments.